Q2 2025 · 13F-HR
M28 Capital Management LPholdings as filed
Filed 2025-08-13 · accession 0000902664-25-003554
$58.6M
Reported value
9
Positions
2025-06-30
Period end
The Brief · M28 Capital Management LP · Q2 2025
AI · grounded in 13F
M28 Capital Management LP established a new position in Wave Life Sciences Ltd WVE valued at $36.8M. The fund also initiated stakes in Invivyd Inc IVVD for $6.6M and TG Therapeutics Inc TGTX for $5.8M. Additional new positions include Fractyl Health Inc GUTS, ProQR Thrapeutics N V PRQR, and Curis Inc CRIS.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $36.8M | 62.8% | 5,664,548 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $6.6M | 11.3% | 9,248,250 | Common | SOLE |
| 88322Q108 | TGTX | TG THERAPEUTICS INC | $5.8M | 9.92% | 161,600 | Common | SOLE |
| 35168W103 | GUTS | FRACTYL HEALTH INC | $3.0M | 5.13% | 1,856,117 | Common | SOLE |
| N71542109 | PRQR | PROQR THRAPEUTICS N V | $2.1M | 3.55% | 1,019,498 | Common | SOLE |
| 231269309 | CRIS | CURIS INC | $1.2M | 2.06% | 521,059 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $1.1M | 1.83% | 185,100 | Common | SOLE |
| 04280A100 | ARWR | ARROWHEAD PHARMACEUTICALS IN | $1.1M | 1.82% | 67,400 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $944,916 | 1.61% | 385,680 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.